Feature|Articles|June 14, 2024
- Pharmaceutical Executive: June 2024
- Volume 44
- Issue 6
Pharmaceutical Executive: June 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive June 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
Beyond the Numbers: Extrapolating Today’s Trends Forwardalmost 2 years ago
Opposite Spectrumsalmost 2 years ago
2024 Pharm Exec Top 50 Companiesalmost 2 years ago
Craig Tooman: Silencing the Distractionsalmost 2 years ago
Regaining Trust in the Pharma Industryalmost 2 years ago
Succession Attack Plan: Get Strategic with Your Critical Rolesalmost 2 years ago
The Healthcare System is Changing—So How Should We Respond?almost 2 years ago
Biotech Performance Remains Tethered to Rate Expectationsalmost 2 years ago
Pharm Exec Exclusive: Mark Cuban Talks Drug PricingAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
3
Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi
4
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
5